Executive Leadership Team
Founder and Chief Executive Officer
Eric Schadt, Ph.D. is founder and CEO of Sema4, a patient-centered health intelligence company built on the idea that more information, deeper analysis, and increased longitudinal engagement of patients will improve the diagnosis, treatment, and prevention of disease. Eric has overseen rapid growth at Sema4 since the company was founded in 2017, driven by the company’s dedication to advancing healthcare through data-driven insights.
Eric is a world-renowned expert on constructing predictive models of disease that link molecular biology to physiology to enable clinical medicine. Over the past 20 years, he has built groups and companies (Merck, Rosetta, Sage Bionetworks, Pacific Biosciences, Icahn Institute, and now Sema4) to elucidate the complexity of human diseases. He has published more than 400 peer-reviewed papers in leading scientific journals and contributed to discoveries relating to the genetic basis of common human diseases such as diabetes, obesity, and Alzheimer’s disease. Now, with Centrellis™, Sema4’s innovative health intelligence platform, Eric is using advanced network analysis to build better models of human health and deliver personalized insights for patients.
Eric also serves as the Dean for Precision Medicine and Mount Sinai Professor in Predictive Health and Computational Biology at Icahn School of Medicine at Mount Sinai. He was previously Founding Director of Icahn Institute for Genomics and Multiscale Biology, and Professor and Chair of the Department of Genetics and Genomic Sciences.
Eric earned his Ph.D. from the University of California, Los Angeles, his M.A. from the University of California, Davis, and his B.S. from California Polytechnic State University-San Luis Obispo.
President and Chief Operating Officer
James Coffin, Ph.D. also known as Jamie, is a pioneer in the healthcare and life sciences sector. As President and Chief Operating Officer at Sema4, he is responsible for business development and growth, sales, client services, and lab operations.
Before joining Sema4, Jamie served as Chief Executive Officer and President at Source Medical Solutions, the leading provider of practice management and EMR solutions in the ambulatory surgical space. Previously, Jamie was Worldwide Vice President and General Manager at Dell, leading the Global Healthcare Life Science business over a six-year period to become the premier healthcare IT services company in the world with $3.5 billion in revenue, and a workforce of approximately 13,000 people. He pioneered Dell’s efforts to apply leading-edge information technology into areas including EMR, data analytics, high performance and cloud computing, personalized medicine, claims processing, medical imaging, and pharmaceutical and biotech drug discovery.
Prior to Dell, Jamie served as Worldwide Vice President of IBM Healthcare and Life Sciences and grew the division to a $6.5 billion business. He was also a Director at Terascala, a company that accelerated big data applications.
Jamie earned his Ph.D. from the University of Arkansas and his B.S. in Chemistry from Louisiana Tech University.
Chief Financial Officer
Isaac Ro has 20 years of financial leadership and experience, with a strong focus on the medical technology and life sciences space. As Chief Financial Officer (CFO) at Sema4, Isaac is responsible for leading all aspects of financial strategy, management, and planning.
Prior to joining Sema4, Isaac served as CFO of Thrive Earlier Detection Corp., a company dedicated to incorporating earlier detection of cancer into routine medical care. In this capacity, he led the sale of Thrive to Exact Sciences Corp. (Nasdaq: EXAS) for $2.15 billion after rapidly scaling the company and raising $257 million in a Series B financing.
Before Thrive, Isaac led the U.S. Medical Technology team at Goldman Sachs where he covered the Life Science Tools, Diagnostics, and Medical Technology sectors. He also held a similar role at SVB Leerink. His career as an equity analyst spanned 16 years, over 60 publicly traded companies, and numerous IPOs and equity financing transactions.
Isaac holds a B.A. in History and was pre-med at Middlebury College.
Daniel E. Clark is a mission-driven advocate with over 15 years of legal experience. As General Counsel for Sema4, Dan oversees all legal and regulatory matters for the company. He also supports Sema4’s academic mission, having worked as a former Lecturer and Research Assistant at the University of Michigan.
Prior to joining Sema4, Dan worked with Eric Schadt, now Sema4’s CEO, and the Icahn Institute in a senior legal role to drive next generation research and industry partnerships. He also practiced in New York City with two leading law firms, clerked for a district judge in the Eastern District of New York, and helped found a boutique startup law firm.
Dan graduated with honors from the University of Michigan School of Law and Pomona College, and has travelled internationally as a Thomas J. Watson Fellow.
Chief Diagnostics Officer
Lisa Edelmann, Ph.D., is a nationally recognized expert in population-based carrier screening, high-throughput clinical diagnostic sequencing, as well as genomic disorders and clinical interpretation of copy number variation. As Chief Diagnostics Officer at Sema4 and co-founder of the company, she is responsible for oversight of clinical operations as they relate to the CLIA laboratories, including clinical reporting, quality assurance, and genetic counseling. She oversees test innovation and development.
Lisa also serves as an Associate Professor in the Department of Genetics and Genomic Sciences at Icahn School of Medicine at Mount Sinai.
Prior to Sema4, Lisa was the Executive Director of the Mount Sinai Genetic Testing Laboratory. Her scientific accomplishments include elucidating the mechanism of chromosome 22q11 rearrangements and involvement in the first molecular sequencing of an entire human chromosome. She has also published extensively on Ashkenazi Jewish genetic disorders and has developed several novel tests, including a test for detection of silent carriers for spinal muscular atrophy, which is licensed nationwide and abroad.
Lisa received her Ph.D. in Molecular Genetics from The Albert Einstein College of Medicine and is certified in Clinical Molecular Genetics and Clinical Cytogenetics by the American Board of Medical Genetics and Genomics.
Chief Marketing Officer
Glenn has over 25 years of experience in leading brand and product strategy and driving successful marketing programs at mission-driven companies and organizations in industries ranging from software and biotech to big data and healthcare.
As Chief Marketing Officer at Sema4, Glenn leads our efforts to build brand awareness and preference for Sema4 products and services by crafting the company’s story, narrative, and positioning strategy with key target audiences. He helped create our key brands, from the Sema4 corporate brand to Centrellis™ for our health intelligence platform, Traversa™ for our exome-based genomic platform, and Sema4 Signal™ for our oncology portfolio of products and services.
Prior to Sema4, Glenn was Chief Marketing Officer at the Icahn Institute for Genomics and Multiscale Biology at Mount Sinai. Previously, he led marketing communications at Pacific Biosciences, where he played an integral role in the company’s successful IPO and rapid scaling of its global marketing and sales. Before PacBio, Glenn led Microsoft’s global brand and marketing strategy team for its flagship Windows products, Server software portfolio, and online services. He also collaborated with Microsoft R&D teams to define the value proposition and roadmap for future products.
Glenn earned his B.A. in Political Science, cum laude, from Yale University.
Chief Data Officer
Andrew Kasarskis has more than 20 years of broad leadership experience in healthcare, biotech, and academia that includes a strong focus on digital analytics and internationally recognized life sciences research.
As Chief Data Officer (CDO), Andrew is responsible for further optimizing Sema4’s health intelligence platform and orchestrating data use and data science to support research, development, and innovation.
Prior to Sema4, Andrew most recently served as Executive Vice President and Chief Data Officer of the Mount Sinai Health System, including the Icahn School of Medicine at Mount Sinai, where he was responsible for supporting patient care, education, research, and innovation through purposeful and appropriate use of the health system’s data assets. Before assuming the CDO role at Mount Sinai, he worked with Founding Director Eric Schadt, now Sema4’s CEO, as Co-Director of the Icahn Institute for Genomics and Multiscale Biology and Vice Chair of the Department of Genetics and Genomic Sciences, in which he also served as Interim Chair.
Dr. Kasarskis’ collaborative research as Professor in the Departments of Genetics and Genomic Sciences and Population Health Science and Policy at the Icahn School of Medicine at Mount Sinai focused on methods and technologies for improving health outcomes through better data acquisition and mining to support patient care decisions and therapeutic and diagnostic development. He created and applied technology across many disease and public health areas including pathogen surveillance, autoimmune conditions such as inflammatory bowel disease and asthma, viral infections, and primary prevention of chronic disease.
Prior to Mount Sinai, Andrew held leadership positions at Pacific Biosciences, Sage Bionetworks and Merck. He has published more than 90 research papers.
Andrew holds a Ph.D. in Molecular and Cellular Biology from the University of California, Berkeley, as well as a B.S. in Biology and a B.A. in Chemistry from the University of Kentucky.
Chief Medical Science Officer
William K. Oh, M.D., is an internationally recognized medical oncologist with over 25 years of clinical and translational research experience and leadership roles at major NCI-designated cancer centers. As Chief Medical Science Officer at Sema4, he is responsible for strategy development, scientific collaborations, clinical development programs, and the adoption of our advanced health intelligence offerings in oncology and a broad spectrum of human diseases.
Before joining Sema4, William served as Chief of the Division of Hematology and Medical Oncology at the Mount Sinai Health System and Deputy Director of The Tisch Cancer Institute at Icahn School of Medicine at Mount Sinai. He was also the Ezra M. Greenspan, M.D. Professor in Clinical Cancer Therapeutics at Mount Sinai. In addition to his current role at Sema4, William continues to care for his patients as Clinical Professor of Medicine at Icahn School of Medicine at Mount Sinai, where he has been recognized by New York Magazine as a Best Doctor for the past decade.
Prior to joining Mount Sinai, William served as Clinical Director of the Lank Center for Genitourinary Oncology and directed the Gelb Center for Translational Research at the Dana-Farber Cancer Institute and Harvard Medical School in Boston. He was also the founding Chair of the Data and Safety Monitoring Committee for Phase I/II Trials at the Dana-Farber/Harvard Cancer Center. In addition to his roles as a widely respected clinician, researcher, and principal investigator of multiple clinical trials, William developed large clinical databases and specimen biorepositories for genitourinary cancers at both Harvard’s Dana-Farber Cancer Institute and Mount Sinai.
William has authored more than 300 articles, reviews, and book chapters related to prostate, renal, bladder, and testicular cancers. He has also edited three books on prostate cancer, and has served in key invited roles for the American Society of Clinical Oncology, the American Cancer Society, and the American Urological Association, including the Guidelines Committee for Advanced Prostate Cancer.
William is a graduate of Yale College and New York University School of Medicine, and completed his training at Brigham and Women’s Hospital and Dana-Farber Cancer Institute.
Chief Product Officer
Tony Prentice is an innovative product developer, strategist, and leader with extensive experience building and running product, marketing, and partnership organizations. His career spans multiple industries including big data, healthcare, mobile applications, customer experience, financial services, and consumer products.
As Sema4’s Chief Product Officer, Tony is responsible for the strategy and execution of all product-related activities including our patient apps, provider apps, information products for health systems and pharma, clinical software, and new product development of our genomic solutions in Oncology and Women’s Health.
Prior to joining Sema4, Tony served as the Vice President of Mobile Payments at American Express, where he built the organization for new commerce products, applications, and mobile wallets. The team delivered enterprise strategy and products including Apple Pay, Android Pay, and the Amex app.
Previously, Tony held other senior product management roles at American Express for Gold Card, Starwood, Hilton and Blue cards. Before American Express, Tony had various product, general manager, and engineering roles at Starbucks, McKinsey & Company, and General Electric.
Chief Business Officer
As Chief Business Officer at Sema4, Kareem Saad is responsible for driving corporate strategy, corporate development, and emerging business initiatives to further accelerate the company’s growth. Kareem has also served as Chief Strategy Officer at Sema4.
Prior to joining Sema4, Kareem was President and Chief Operating Officer at Apervita, Inc., overseeing its transformation to a product- and value-based care and quality measurement technology company. Kareem previously served as Chief Commercial Officer/EVP of Strategy and Business Development at SourceMed, a PE-backed healthcare IT and services company focused on delivering practice management technology solutions to the outpatient market, where he led a series of transactions that culminated in the sale and merger of the company with Surgical Information Systems.
Kareem also served as a Director in Dell’s Healthcare and Life Sciences division, where he was responsible for managing a $180 million healthcare partner program. Before that, he held a number of executive roles in biotech and healthcare technology startups, as well as leading the Information Based Medicine Commercial Group at IBM’s Healthcare Life Sciences group helping grow that business to $100 million in less than five years.
Kareem holds a B.S. in Biochemistry and Molecular Biology with a minor in Computer Science from the University of British Columbia and an M.B.A with a concentration in Economics and Finance from the University of Chicago.
Chief Science Officer
Gustavo Stolovitzky is a world-renowned expert in computational biology, disease modeling and nano-biotechnology, with over 25 years of experience in high throughput data analysis for biology and the application of technology to solve biomedical problems.
As Chief Science Officer, Gustavo has a key role in developing the strategic research direction of the company and is responsible for advancing our platform of algorithms to help researchers, health system partners, providers and patients translate the information contained in health data into actionable knowledge.
Gustavo spent 23 years at IBM Research, where he was appointed IBM Fellow, the highest technical honor bestowed by IBM. His most recent role was the Founding Chair of the Exploratory Life Sciences Program at IBM Research and, previously, he was the Director of the Translational Systems Biology and Nanobiotechnology Program. He has authored more than 180 articles, reviews, and book chapters, and holds over 80 granted patents.
He is well known as the founder of the DREAM Challenges, where he nucleated a community of more than 25,000 researchers applying AI to biomedicine and championed the values of open science and data sharing, as well as rigorous evaluation of performance and reproducibility of algorithms. Through the DREAM Challenges and his own research, Gustavo addressed core challenges in biomedical research, with great influence in the areas of biological network inference, cancer genomics, and prediction of treatment response and disease outcome.
Gustavo obtained his M.S. degree in Physics from the University of Buenos Aires, and his Ph.D. in Engineering and Applied Sciences at Yale University. He completed his post-doctoral training at The Rockefeller University. Gustavo has earned several awards, including Yale’s “Henri Prentiss Becton Award”, HENAAC’s “Pioneer Award”, Argentina’s Government “Premio Raíces” and has been elected Fellow of several professional associations, including the American Physical Society, the American Association for the Advancement of Sciences, and the International Society for Computational Biology.
Chief People Officer
Karen has more than 25 years of experience in strategy, organization, and leadership development, and human resources, including a decade in the healthcare and life sciences industry. At Sema4, she is responsible for all elements of the people strategy, with a particular focus on talent, diversity, culture, and employee experience.
Prior to joining Sema4 in September 2020, Karen was Vice President of Human Resources for Commercial Solutions at Syneos Health, a fully integrated biopharmaceutical solutions organization. Among other things, she led the Global Commercial team through a merger and transition to processes as a public company. Prior to joining Syneos Health, she has held senior HR roles at other companies in the healthcare space, including inVentiv Health Consulting and Memorial Sloan Kettering Cancer Center. Before that, Karen held positions at large global organizations such as Goldman Sachs, IBM, and PricewaterhouseCoopers.
Karen has a collaborative and flexible approach to designing and delivering high performance solutions. She is a certified executive coach who has designed and implemented groundbreaking development programs to stimulate leadership and improve cultures, and is certified in an array of assessment instruments. Karen has two children and is also an active member of the Leukemia & Lymphoma Society. She earned her M.B.A from The George Washington University and her B.A. from Hobart and William Smith Colleges.
SVP & GM Oncology Solutions and Emerging Markets
Michelle Zimmerman is a seasoned healthcare executive with expertise building and growing companies in digital health, health services, health insurance, and health information.
At Sema4, Michelle serves as the Senior Vice President and General Manager of Oncology Solutions and Emerging Markets. In her role, Michelle leads the oncology business unit, scaling our data-driven solutions to enable precision cancer care. She oversees product strategy, market insights and analytics, and integrating the oncology portfolio to provide the maximum benefit to providers and patients. Michelle also oversees the development and scaling of new lines of business that leverage the Centrellis® platform to transform the standard of care across new areas of disease and wellness.
Prior to joining Sema4, Michelle served in leadership positions across a number of healthcare growth companies. She served as Senior Vice President, U.S. Operations & Business Development, for Mavencare, a venture-backed home health company, and as Chief Innovation Officer at AlphaCare, a managed care plan acquired by Magellan Health. She was also a founding member of Aetna’s commercial innovation team, where she built and incubated healthcare technology – enabled start-ups backed by the company.
Michelle began her career in management consulting with the Boston Consulting Group and then in corporate law with Paul Weiss, Rifkind, Wharton & Garrison. She also has experience on the policy side of healthcare and has published work on the topic of resource allocation decision making.
Michelle holds J.D. and M.B.A degrees from the University of Toronto and a B.A with honors in Economics and Criminology.
Dave is an advisor to Sema4, supporting the leadership team on strategic, organizational, business development, operational, and financial and capital formation matters. He previously served as the executive chair of Sema4.
Dave is also currently an operating partner and co-investor at Waud Capital Partners where his efforts focus on several portfolio companies within the health and health technology services sector. He has invested in and served in various governance roles in a number of private and public companies during his career.
Dave was previously a senior partner and director at Bain & Company with leadership responsibility for the health plan, provider, and healthcare technologies and services sectors. Before that, he served as EVP and COO for NDC Health, SVP at APM/Computer Science Corporation, and CEO of two specialty reinsurers that were sold to an industry consolidator. Dave earlier founded, built, and sold Canada Prosthetics and was a Northwestern University Med School faculty member.
Dave received an MBA and M.A. degrees with highest honors from Northwestern University.